Gynae BT_Lucknow_2018

EBRT for GYN Cancer treatment

• Elective dose including draining lymphatic system

• Boost to regional pathologic nodes

• Boost to primary tumor if brachytherapy is not feasible

• Dose needed for tumor control too high for surrounding OAR

• Reduction according to ALARA, as low as reasonably

achievable

• Dose constraints and DVH parameters help to balance

between tumor dose and OAR dose